Fig. 1From: A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndromeChange in mean ADAMS subscale scores from screening to week 12 (N = 18). Note. ADAMS = Anxiety, Depression and Mood Scale; Error bars represented standard error at each time point; * p < .05, **p < .01, ***p < .001Back to article page